Table 2. Methylation before and after stop of MTX therapy.
| T0 (before start MTX) | T1 (after stop MTX) | p-value | ||
|---|---|---|---|---|
| Cellular methylation | ||||
| SAM (nmol/L), median (range) | (n = 77) | 109.0 (71.0–245.0) | 99.0 (44.0–151.0) | <0.001* |
| SAH (nmol/L), median (range) | (n = 77) | 13.5 (8.1–78.2) | 12.9 (6.4–56.2) | 0.234 |
| SAM:SAH ratio, mean ± SD | (n = 77) | 8.0 ± 2.8 | 7.4 ± 3.1 | 0.207 |
| Global DNA methylation | ||||
| LINE1 –methylation (%), mean ± SD | (n = 80) | 65.1 ± 1.8 | 66.5 ± 1.9 | <0.001* |
T0: before start MTX; T1: after stop MTX. Mean percentage methylation of CpG sites in LINE1 (%) and plasma SAM—SAH levels (nmol/L) at T0 vs. T1; mean ± SD or median (range) based on normal distribution of data.